Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.42 |
| ▸ | CNR2 | P34972 | 15/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926216 | 0.91 | PLA2G2A (0.35) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL2924740 | 0.84 | KMT2A (0.37) | CNR1CNR2 | |
| SCHEMBL556503 | 0.83 | HDAC8 (0.36) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL4090552 | 0.82 | CA1 (0.43) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL2923636 | 0.82 | CNR1 (0.50) | CNR1CNR2HPGD | |
| SCHEMBL1744893 | 0.81 | GPR119 (0.41) | HTTSMN1; SMN2 | |
| SCHEMBL557680 | 0.81 | GPR119 (0.41) | HTTSMN1; SMN2 | |
| SCHEMBL4076440 | 0.79 | ITGB3 (0.42) | — | |
| SCHEMBL22402873 | 0.79 | TDP1 (0.47) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL3474501 | 0.79 | TDP1 (0.47) | HPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722620-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-05-13 | — | — | US | disclosed |
| EP-2256129-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-1991576-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2010-09-29 | — | — | EP | disclosed |
| US-20090137454-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137454-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | CNR1 3956/4885CNR2 4031/4885HPGD 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.